Cytek Biosciences posts record Q4 results. Cytek Biosciences delivered record fourth quarter revenue of $62.1 million, significantly exceeding expectations and demonstrating strong market demand for its flow cytometry solutions. The company's Aurora Evo platform drove substantial growth, while recurring revenue streams expanded notably, indicating a shift toward more predictable business operations. Management has guided 2026 revenue between $205 million and $212 million, representing approximately 30 percent growth year-over-year. This ambitious outlook reflects confidence in sustained demand for the company's core products and expanding customer adoption. The recurring revenue momentum is particularly significant for investors, as it suggests improving customer retention and lifetime value.
Post from MarketNews_en
Log in to interact with content.